The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus

Life Sciences

Volumn 60, Issue 9, 1997, Pages

  Helsley, Scott ^a   Rabin, Richard A ^a   Winter, J C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

12 hydroxyibogamine; drug induced stimulus control; hallucinogen; harmaline; ibogaine; time course

Indexed keywords

DRUG METABOLITE; HARMALINE; IBOGAINE; NORIBOGAINE; WATER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DISCRIMINATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; STIMULUS GENERALIZATION;

ANIMALS; DISCRIMINATION LEARNING; HALLUCINOGENS; HARMALINE; HUMANS; IBOGAINE; MALE; RATS; RATS, INBRED F344; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

ANIMALIA;

EID: 0031584698     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(96)00703-5     Document Type: Article

References (26)

1. 1. S.D. GLICK, K. ROSSMAN, S. STEINDORF, I.M. MAISONNEUVE, and J.N. CARLSON, Eur. J. Pharmacol. 195 341-345 (1991).
2. 2. S.D. GLICK, M.E. KUEHNE, J. RAUCCI, T.E. WILSON, D. LARSON, R.W. KELLER Jr., and J.N. CARLSON, Brain Res. 657 14-22 (1994).
3. 3. S.I. DWORKIN, S. GLEESON, D. MELONI, T.R. KOVES, and T.J. MARTIN, Psychopharmacology 117 257-261 (1995).
4. 4. S.L.T CAPPENDIJK and M.R. DZOLJIC, Eur. J. Pharmacol. 241 261-265 (1993).
5. 5. A.H. REZVANI, D.H. OVERSTREET, and Y. LEE, Pharmacol. Biochem. Behav. 52 615-620 (1995).
6. 6. S.G. SHEPPARD, J. Subs. Abuse Treatment 11 379-385 (1994).
7. 7. H. LOTSOF, U.S. Patent 4,499,096; Rapid method for interrupting the narcotic addiction syndrome. (1985).
8. 8. H. LOTSOF, U.S. Patent 4,587,243; Rapid method for interrupting the cocaine and amphetamine abuse syndrome. (1986).
9. 9. H. LOTSOF, U.S. Patent 4,857,523; Rapid method for interrupting the alcohol dependency syndrome. (1989).
10. 10. H. LOTSOF, U.S. Patent 5,026,697; Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome. (1991).
11. 11. D.C. MASH, J.K. STALEY, M.H. BAUMANN, R.B. ROTHMAN, and W.L. HEARN, Life Sciences 57 PL 45-50 (1995).
12. 12. L.B. HOUGH, S.M. PEARL, and S.D. GLICK, Life Sci. 58 PL 119-122 (1996).
13. 13. F.C. COLPAERT, Methods of Assessing the Reinforcing Properties of Abused Drugs. M. A. Bozarth (Ed), 341-372, Springer, Berlin, (1990).
14. 14. J.C. WINTER, NIDA Research Monograph Series 146 157-182 (1994).
15. 15. M.D. SCHECHTER and T.L. GORDON, Eur. J. Pharmacol. 249 79-84 (1993).
16. 16. D. FIORELLA, R.A. RABIN and J.C. WINTER, Psychopharmacology 119 222-230 (1995).
17. 17. J.C. WINTER and R.A. RABIN, J. Pharmacol. Exp. Ther. 263 682-689 (1992).
18. 18. S.D. GLICK, S.M. PEARL, J. CAI, and I.M. MAISONNEUVE, Brain Res. 713 294-297 (1996).
19. 19. S.M. PEARL, K. HERRICK-DAVIS, M. TEITLER, and S.D. GLICK, Brain Res. 675 342-344 (1995).
20. 20. R.T. LAYER, P. SKOLNICK, C.M. BERTHA, U.K. BANDARAGE, M.E. KUEHNE, and P. POPIK, Eur. J. Pharmacol. 309 159-165 (1996).
21. 21. J.K. STALEY, Q. OUYANG, J. PABLO, W.L. HEARN, D.D. FLYNN, R.B. ROTHMAN, K.C. RICE, and D.C. MASH, Psychopharmacology 127 10-18 (1996).
22. 22. W.D. BOWEN, B.J. VILNER, W. WILLIAMS, C.M. BERTHA, M.E. KUEHNE, and A.E. JACOBSON, Eur. J. Pharmacol. 279 R1-R3 (1995).
23. 23. D.C. MASH, J.K. STALEY, J.P. PABLO, A.M. HOLOHEAN, J.C. HACKMAN, and R.A. DAVIDOFF, Neuroscience Lett. 192 53-56 (1995).
24. 24. E.B. NIELSEN, F.J. WHITE, A.M. HOLOHEAN, P.M. CALLAHAN, and J.B. APPEL, Life Sci. 31 2433-2439 (1982).
25. 25. P.A. PALUMBO and J.C. WINTER, Pharmacol. Biochem. Behav. 43 1221-1226 (1992).
26. 26. R.A. GLENNON, R. YOUNG, J.M. JACYNO, M. SLUSHER, and J.A. ROSECRANS, Eur. J. Pharmacol. 86 453-459 (1983).